Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00652899 · OUTCOME

Number of Patients With In Vivo Expansion of Infused Allogeneic Natural Killer (NK) Cell Product

Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer · Source last updated 2017-12-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Patients
Interval / dispersion
Not reported
Time frame
Day 12-14

What was measured

Detection of an absolute donor derived cell count of \> or = 100 cells/mL after NK cell infusion.

Groups in this outcome

Ovarian/Fallopian Tube/Peritoneal Cancer Patients

This group includes patients with recurrent ovarian, fallopian tube or primary peritoneal cancer who received at least one dose of chemotherapy (cyclophosphamide 60 mg/m\^2 and fludarabine 25 mg/m\^2 for 2 doses, and aldesleukin 10 million units for 6 doses), infusion of natural killer cells (1.5-8.0 \* 10\^7 kg) and/or total body irradiation per protocol (200 Gy on Day 1 preceding natural killer cell infusion).

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Ovarian/Fallopian Tube/Peritoneal Cancer Patients12

Reported measurements

Source class 1
Values in Patients · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Ovarian/Fallopian Tube/Peritoneal Cancer Patients0Not reportedNot reportedNot reportedNot reported
Complete source fields
anticipated Posting Date
2010-05
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        0
denoms
  1. counts
    1. group Id
      OG000
      value
      12
    units
    Participants
description
Detection of an absolute donor derived cell count of \> or = 100 cells/mL after NK cell infusion.
groups
  1. description
    This group includes patients with recurrent ovarian, fallopian tube or primary peritoneal cancer who received at least one dose of chemotherapy (cyclophosphamide 60 mg/m\^2 and fludarabine 25 mg/m\^2 for 2 doses, and aldesleukin 10 million units for 6 doses), infusion of natural killer cells (1.5-8.0 \* 10\^7 kg) and/or total body irradiation per protocol (200 Gy on Day 1 preceding natural killer cell infusion).
    id
    OG000
    title
    Ovarian/Fallopian Tube/Peritoneal Cancer Patients
param Type
NUMBER
reporting Status
POSTED
time Frame
Day 12-14
title
Number of Patients With In Vivo Expansion of Infused Allogeneic Natural Killer (NK) Cell Product
type
PRIMARY
unit Of Measure
Patients

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice